NetFlix Inc vs uniQure N.V. Ordinary Shares — how do they compare? NetFlix Inc trades at $70.89 (market cap $293.39B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: NetFlix Inc is far larger — about 198.2× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 126 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NFLX | QURE | |
|---|---|---|
Market Cap | $293.39B | $1.48B |
Volume | 27,708,338 | 2,488,780 |
Sector | Media | Health |
52-Week High | $124.13 | $70.59 |
52-Week Low | $67.06 | $9.03 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $298.57B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $70.61, up 0.44% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.80, beating expectations, and maintains robust profitability with 28.22% net margin and 49.54% ROE. Recent news highlights content expansion into live sports and positive analyst sentiment with a $89.39 consensus price target.
Netflix presents a compelling growth story with expanding margins and strategic content investments, though technical indicators signal near-term caution. The stock offers 27% upside to analyst targets but faces competition and execution risks in live sports expansion.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →